Halle Moore, MD, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, shares her highlights from at the San Antonio Breast Cancer Symposium (SABCS) 2022, including the the Phase II RIGHT Choice (NCT03839823) trial, comparing endocrine therapy with the CDK4/6 inhibitor ribociclib to combination chemotherapy in the first-line treatment setting for premenopausal woman with aggressive hormone receptor-positive, HER2-negative (HR+/HER2-) advanced breast cancer. The RIGHT Choice demonstrated that the time to response is comparable for both endocrine therapy plus ribociclib and chemotherapy, and progression-free survival (PFS) improved with endocrine therapy plus ribociclib. Additionally endocrine therapy plus ribociclib was better tolerated than combination chemotherapy. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.